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In the context of adoptive T cell transfer (ACT) for cancer treatment, it is crucial to
generate in vitro large amounts of tumor-specific CD8T cells with high potential to
persist in vivo. PD-1, Tim3, and CD39 have been proposed as markers of tumor-specific
tumor-infiltrating CD8T lymphocytes (CD8 TILs). However, these molecules are highly
expressed by terminally differentiated exhausted CD8T cells (Tex) that lack proliferation
potential. Therefore, optimized strategies to isolate tumor-specific TILs with high
proliferative potential, such as Tcf1+ precursor exhausted T cells (Tpe) are needed to
improve in vivo persistence of ACT. Here we aimed at defining cell surface markers
that would unequivocally identify Types for precision cell sorting increasing the purity
of tumor-specific PD-1+ Tcf1+ Tpe from total TILs. Transcriptomic analysis of Tpe
vs. Tex CD8 TIL subsets from B16 tumors and primary human melanoma tumors
revealed that Tpes are enriched in Slamf6 and lack Entpd1 and Havcr2 expression,
which encode Slamf6, CD39, and Tim3 cell surface proteins, respectively. Indeed, we
observed by flow cytometry that CD39– Tim3– Slamf6+ PD-1+ cells yielded maximum
enrichment for tumor specific PD-1+ Tcf1+ OT1 TILs in B16.OVA tumors. Moreover,
this population showed higher re-expansion capacity upon an acute infection recall
response compared to the CD39+ counterparts or bulk PD-1+ TILs. Hence, we report
an enhanced sorting strategy (CD39– Tim3– Slamf6+ PD-1+) of Tpes. In conclusion, we
show that optimization of CD8 TIL cell sorting strategy is a viable approach to improve
recall capacity and in vivo persistence of transferred cells in the context of ACT.
Keywords: tumor-infiltrating CD8T cells, precursor exhausted T cells, memory-like CD8T cells, adoptive cell
transfer, melanoma
INTRODUCTION
Sustained antigenic stimulation of CD8T cells in cancer and chronic infection
leads to an exhausted state characterized by high expression of multiple inhibitory
receptors, reduced cytotoxicity, and re-expansion capacity (1–3). Far from being a
“failed” immune response, this Tox-driven exhaustion epigenetic program is essential
for the persistence of CD8T cells in the context of sustained antigenic stimulation
(4–6). If CD8T cells fail to activate the exhaustion program (e.g., when Tox is
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disrupted), persistent antigenic stimulation erodes
immunodominant clones by mechanisms such as
activation-induced cell death (4, 6).
Recent studies have shown that the pool of exhausted
CD8 tumor-infiltrating lymphocytes (TILs) is maintained within
the tumor by a precursor subset (memory-like or precursor
exhausted, Tpe) that expresses the transcription factor T cell
factor 1 (Tcf1), encoded by Tcf7 (7, 8). Tpe cells can self-renew
and differentiate into exhausted cells (Tex). Tex exert (limited)
cytotoxic functions while avoiding overstimulation but they lack
proliferative potential (8–10).
In the context of adoptive T cell transfer (ACT) for cancer
treatment, it is crucial to generate in vitro large amounts of
tumor-specific CD8T cells with high potential to persist in vivo.
To attain tumor-specificity, CD8T cells are typically isolated
from tumor samples. However, not all tumor-infiltrating CD8
lymphocytes (TILs) are tumor-specific (11), and the isolation
of tumor-specific TILs is far from trivial. Different studies have
shown that tumor-specific TILs can be enriched by means of
surface expression of PD-1, Tim3, and CD39 among others (11–
15). However, these markers are highly expressed by terminally
differentiated Tex, and hence TIL isolation based on these
markers enriches in cells with very limited proliferation potential.
Therefore, novel strategies to isolate tumor-specific TILs with
high proliferative potential, such as Tpe, are needed for improved
in vivo persistence in ACT. Here we aimed at defining an
improved selection strategy to increase the purity of tumor-
specific Tpe from total TILs.
MATERIALS AND METHODS
Transcriptomic Analyses
For the analysis of CD8 TILs melanoma patients we downloaded
processed gene expression data [log2 (TMP+1)] fromNCBIGEO
[accession GSE120575, (16)]. Only non-lymph node samples
were considered. High-quality cells were filtered based on
number of detected genes (between 1,000 and 6,000) and
percentage of TPMs mapping to ribosomal genes (<10%) (1482
TILs from 23 patients). PD-1+ CD8T cells were further filtered
from other immune cell infiltrates based on the co-expression
of CD2, CD8A, CD8B, PDCD1 [log2 (TMP+1) >= 1], lack
of CD4 expression (TPM = 0) and low expression of non-T
cell genes FCER1G, TYROBP, SPI1, IGKC, IGJ, IGHG3 [log2
(TMP+1) <3]. Next, we performed differential gene expression
analysis between TCF7+ [log2 (TMP+1) > 0] and TCF7- (TPM
= 0) cells (cutoff based on the TCF7 expression distribution
of Supplementary Figure 1), using Seurat v2.3.4 and MAST
v1.8.2 (17) with parameters min.pct = 0.1, min.diff.pct = 0.01,
logfc.threshold = 0.1. For visualization, in the human volcano
plot (Figure 1A) we truncated log (fold-change) values at 3 and
–log (p-value) at 25. For human TIL virtual gating strategy
(Figures 1B–D) we used 1 UMI as a cut-off value to define
PDCD1+, HAVCR2+, ENTPD1+ and SLAMF6+ cells.
For analysis of murine melanoma CD8 TILs we used
processed data (UMI count matrix) from NCBI GEO [accession
GSE116390, (18)]. Briefly, gene expression values were
normalized and scaled as log(UMI counts / sum UMI count in
cell ∗ 10,000+ 1). Next, differential expression betweenmemory-
like/progenitor exhausted subset vs. terminally exhausted subsets
[as defined in Carmona et al. (18)] was conducted using Seurat
and MAST with parameters min.pct = 0.1, min.diff.pct=0.1,
and logfc.threshold = 0.25. For the murine TIL virtual gating
strategy (Figures 1B–D), we used 1 UMI as a cut-off value to
define Pdcd1+, Havcr2+, Entpd1+, and Slamf6+ cells.
Mice
C57BL/6 (B6) mice were purchased from ENVIGO (Gannat,
France) and CD45.1 OT1 mice were bred at the animal
facility (Epalinges) of the University of Lausanne. Mice were
all females, 7–10 weeks old, and maintained in conventional
facilities of the University of Lausanne. This study was approved
by the Veterinary Authority of the Swiss Canton of Vaud
(authorization VD3360.c) and performed in accordance with
Swiss ethical guidelines.
Melanoma Tumor Model
The B16.OVA cell line was generated as previously described
[refers to B16.N4 (19)]. Cells underwent a maximum of two
passages from thawing to the time of engraftment and were
cultured in complete DMEM (10% FCS (10270-106, Gibco),
1% Penicilin/Streptomycin (15070-063, Gibco), 0.1% β-mercapto
ethanol (31350-010, Gibco), 1% Hepes (5-31F00-H, Amimed) in
DMEM (31966-021, Gibco).
2 × 105 B16.OVA cells were subcutaneously (s.c.) engrafted
on the right flank of B6 mice. After 6 days, 105 CD45.1 OT1T
cells were intravenously (i.v.) transferred. One day later, mice
were s.c. vaccinated with 10 µg SIINFEKL (N4) peptide (Protein
and Peptide Chemistry Facility, UNIL) and 50 µg CpG (ODN
1826, Microsynth).
Tumors were harvested 21 days post tumor engraftment
and dissociated with the Tumor Dissociation Kit (130-096-730,
Miltenyi Biotec) following manufacturer’s instructions before
antibody staining for flow cytometry. Tumors of 6–10 individual
mice were pooled before marker based cell sorting and transfer to
secondary hosts.
Listeria monocytogenes. OVA Infection
Three hundred flow cytometry-sorted naïve CD8+ CD45.1 cells
from spleens of OT1 mice, or 300 OT1 cells (PD-1+, PD-1+
Tim3– Slamf6+ CD39–, or PD-1+ Tim3– Slamf6+ CD39+)
isolated from tumors of B16.OVA tumor bearing mice, were i.v.
transferred to naïve B6 secondary hosts. The same day, mice
were infected i.v. with 2000 colony forming units (cfu) of OVA
expressing Listeria monocytogenes (Lm-OVA).
Seven days post-infection, spleens from infected mice were
collected, smashed through a 70µm diameter cell strainer
(352350, Falcon) and red blood cells were lysed with RBC
lysis buffer (158904, Qiagen) before antibody staining for flow
cytometry analysis of OT1 cells.
Ex vivo Stimulation of OT1 Cells
Mouse splenocytes were stimulated with 10µg/ml SIINFEKL
peptide or 10 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml
ionomycin as positive control (Sigma-Aldrich) for 4 h at 37◦C
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in complete DMEM. Unstimulated cells were used as negative
control. BD GolgiPlug and GolgiStop (BD Biosciences) were
added to the cells 30min upon starting the stimulation assay.
Surface and Intracellular Antibody Staining
for Flow Cytometry
Surface antibody staining was performed in darkness for 20min
at 4◦C in FACS buffer (2% FCS, 2 mmol/L EDTA in PBS).
Cells were stained with the following antibodies: CD3-AF700 (cl.
17A2, eBioscience), CD8-PerCp-Cy5.5 (cl. 53-6.7, eBioscience),
CD45.1-BV650 (cl. A20, BioLegend), PD-1-BV711 (cl. 29F-1A12
BioLegend), Tim-3-BV421 (cl. RMT3-23, BioLegend), CD39-
PE-Cy7 (cl. Duha59, BioLegend), and Slamf6-APC (cl. 330-
AJ, BioLegend). LIVE/DEAD fixable Aqua fluorescent reactive
dye (L34957, Thermo Fisher Scientific) or Fixable Viability Dye
eFluor 506 (65-0866-14, Thermo Fisher Scientific) was used for
dead cell discrimination. For intracellular Tcf1 staining, cells
were fixed and permeabilized with Foxp3/Transcription Factor
Staining Buffer Set (00-5523-00, eBioscience) according to the
manufacturer’s instructions and stained for 1 h at 4◦C with
Tcf-1-Rabbit (2203, Cell Signaling) followed by 15 min Fab
aRabbit-PE-TexasRed staining (cl. Poly464, BioLegend), both in
Perm/wash buffer. For intracellular cytokine staining, cells were
fixed (Fixation buffer; 420801 BioLegend), and permeabilized
(Perm/wash buffer; 421002 BioLegend) before being stained with
IFNγ-PerCp-Cy5.5 (cl. XMG1.2, eBioscience) and TNFα-APC-
Cy7 (cl. MP6-XT22, BioLegend). Samples were analyzed with
LSRII flow cytometer (BD Biosciences). For flow cytometry cell
sorting, cells were sorted with FACS Aria (BD Biosciences)
following the gating strategy from Supplementary Figure 3A
and collected in complete DMEM.
Data and Statistical Analysis
Flow cytometry data were analyzed with FlowJo (TreeStar).
Graphs and statistical analysis were made with Prism (GraphPad
Software) except scRNAseq data which was analyzed with R
(described above). Specific statistical analyses are described in
figures’ captions. P-values are coded as ∗p > 0.05, ∗∗p > 0.01,
∗∗∗p > 0.001, and ∗∗∗∗p > 0.0001.
RESULTS
CD39– Tim3– Slamf6+ PD-1+ CD8 TILs
Show the Highest Enrichment for Tcf1+
Cells in Mouse and Human Melanoma
Tumors
To identify surface markers of tumor-specific Tcf1+ PD-
1+ Tpe that would allow their selection for ACT, we
performed a differential gene expression analysis of Tcf7+
Pdcd1+ (Tpe) vs. Tcf7- Pdcd1+ (Tex) from scRNAseq data
of CD8 TILs from murine B16 (18) and human primary
melanoma tumors [publicly available data from Sade-Feldman
et al. (16)] (Supplementary Tables 1, 2). In both mouse and
human melanoma tumors we observed that Tcf7+ Pdcd1+
Tpe were enriched in Slamf6 and depleted of Havcr2 and
Entpd1, which encode Slamf6, Tim3, and CD39 cell surface
proteins, respectively (Figure 1A). Thus, we hypothesized that
the expression patterns of Slamf6, Tim3, and CD39 may help
discriminating Tpe from Tex among tumor-specific TILs.
First, we explored the plausibility of this hypothesis in silico. A
previous report already showed that tumor-specific (identified by
tetramer staining) Tim3- Slamf6+ cells were enriched in Tcf7+
cells compared to Tim3+ Slamf6- counterparts (7). Here we used
Pdcd1 expression (which encodes for PD-1) as a surrogatemarker
of tumor specificity (14) and observed that indeed, Pdcd1+
Havcr2– Slamf6+ cells were enriched in Tcf7+ cells compared
to bulk Pdcd1+ or Pdcd1+ Havcr2– cells (Figure 1B). However,
among Pdcd1+ Tim3– Slamf6+ cells we found heterogeneous
expression of Entpd1, a marker of Tex, both in murine and
human melanoma tumors (Figure 1C).
In fact, Pdcd1+ Tim3– Slamf6+ Entpd1− cells showed
increased enrichment for Tcf7+ cells compared to their Entpd1+
counterparts (Figure 1D). Thus, at the mRNA level, Entpd1–
(CD39) Havcr2– (Tim3) Slamf6+ Pdcd1+ cells show the highest
enrichment for Tcf7+ cells.
Next we sought to verify whether the surface expression
of these markers could be used to identify Tpe cells by
flow cytometry. To this end, we analyzed Tcf1 expression on
total PD-1+ endogenous and transferred OT1 CD8 TILs from
B16.OVA tumors before and after marker-based cell selection.
We confirmed that CD39– Tim3– Slamf6+ PD-1+ cells showed
the highest enrichment for Tcf1+ cells in both endogenous
and transferred tumor-specific OT1 cells (Figure 1E), which
accounted for the ∼3.5% of total endogenous or OT1 TILs
(Figure 1F). CCR7 was also highly expressed in Tpes compared
to Tex cells (Supplementary Tables 1, 2) but antibody staining
of this chemokine receptor was poor and did not select Tcf-1+
CD8T cells in B16.OVA tumors (Supplementary Figure 2A).
In conclusion, selection of CD39– Tim3– Slamf6+ PD-
1+ TILs by surface antibody staining allows for maximum
enrichment of Tcf1+ tumor-specific Tpe.
CD39– Tim3– Slamf6+ PD-1+ CD8 TILs
Show Increased Re-expansion Capacity
and Functionality Compared to CD39+
Counterparts or Bulk PD-1+ TILs
Tpe cells have been described as those cells that maintain
antigen-specific responses in the context of chronic infection
and tumors (8, 9). Therefore, highly homogenous Tpe cell
products would be ideal in the context of ACT to improve
persistence of transferred cells in the hosts. Thus, we investigated
whether our newly described CD39– Tim3– Slamf6+ PD-1+
TIL subset display better recall responses and persistence in vivo
compared to bulk TIL populations. To this end, either 300 PD-
1+, PD-1+ Tim3– Slamf6+ CD39–, or PD-1+ Tim3– Slamf6+
CD39+OT1 CD8 TILs cells were isolated from B16.OVA tumors
21 days post-tumor engraftment following the gating strategy
of Supplementary Figure 3A and transferred to a secondary
host that was infected on the same day with OVA-expressing
Listeria monocytogenes (Lm-OVA). Naïve OT1 cells were also
transferred as control (Figure 2A). Seven days post-infection
(PI), we observed increased frequencies of transferred OT1 cells
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FIGURE 1 | Surface marker identification of PD-1+ Tcf1+ TILs. (A) Volcano plots showing differential gene expression between Pdcd1+ Tcf7+ (encoding PD-1 and
Tcf1, respectively) progenitor exhausted (Tpe) and Pdcd1+ Tcf7– terminal exhausted (Tex) CD8+ T cells. Genes with p-value < 0.01 (–log10[p-value] > 2) are plotted.
(B) Percentage of Tcf7+ cells in Pdcd1+, Pdcd1+ Tim3– or Pdcd1+ Tim3– Slamf6+ CD8+ TILs. (C) Pie charts showing mean frequency of Entpd1– and Entpd1+
(which encodes CD39) cells in total Pdcd1+ Tim3– Slamf6+ CD8+ TILs. (D) Percentage of Tcf7+ cells in Pdcd1+ Tim3– Slamf6+ Entpd1– vs. Pdcd1+ Tim3–
Slamf6+ Entpd1+ cells. (A–D) show analysis of scRNAseq data from murine B16 tumors and human melanoma patients’ primary tumors. (E) Representative dotplots
and quantification of the percentage of Tcf1+ cells in endogenous CD8+ PD-1+ and transferred PD-1+ OT1 cells from B16.OVA tumors before and after subset
definition based on the expression of Tim3, Slamf6, and CD39. A repeated measure 1-way ANOVA was performed followed by Tukey’s multiple comparison test (n =
13–16). Three mice were excluded in the left panel for having acquired <100 endo PD1+ cells. (F) Percentage of each marker based subset in total endogenous
CD8+ and OT1 cells from B16.OVA tumors (n = 16) (E,F) show flow cytometry analysis of CD8+ TILs where each dot represents a mouse. Pooled data of two
independent experiments.
in mice receiving PD-1+ Tim3– Slamf6+ CD39– cells compared
to those receiving their CD39+ counterparts or total PD-1+
OT1 CD8 TILs (Figure 2B), indicating their enhanced recall
response and persistence. At 7 days PI, most transferred cells were
Tcf1– (Figure 2C), consistent with previous reports showing that
tumor-specific Tcf1+ cells differentiate into Tcf1– negative cells
(7, 8).
In addition to the enhanced expansion capacity, PD-1+
Tim3– Slamf6+ CD39– cells showed enhanced functionality in
the recall response compared to their CD39+ counterparts, with
increased frequency in IFNγ, TNFα and IFNγ+TNFα double
expressing cells (Figure 2D) as well as increased expression of
these molecules (Figure 2E).
Altogether, selection of CD39– Tim3– Slamf6+ cells among
PD-1+ TILs led to an enhanced persistence and functionality of
transferred TILs in a recall response compared to their CD39+
counterparts or bulk PD-1+ TILs.
DISCUSSION
ACT therapy of in vitro expanded TILs has shown promising
clinical efficacy in melanoma patients (20). However, poor
in vivo persistence of transferred cells remains a major
limitation. TIL culture conditions can be optimized to obtain
cell products with longer in vivo persistence (21–23). However,
these protocols bypass selection of tumor-specific T cells,
limiting the anti-tumor capacity of expanded T cells. Here
we propose a flow cytometry gating strategy that enables
the selection of tumor-specific TILs with higher in vivo
persistence and functionality in recall responses compared to
bulk populations.
In the tumor, high affinity T cells show increased PD-1
expression compared to low affinity counterparts (19). Therefore,
isolation of PD-1+ cells may allow selection of high affinity
T cells, which show enhanced tumor control than low affinity
T cells (19). Moreover, high affinity T cells may include those
recognizing mutated self-antigens (neoantigens) which have
been shown to respond to vaccination (24, 25) and anti-PD-1
therapy (24).
We propose the use of PD-1 as a marker of tumor specificity
as previously described (14) while simultaneously gating out
Tim3+ and CD39+ cells. Even though Tim3 and CD39 can
further enrich in tumor-specific TILs (11, 13, 15), this is achieved
at the expense of a dramatic loss of in vivo recall capacity. Recent
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FIGURE 2 | Re-expansion capacity assessment of PD-1+ TIL subsets in Lm-OVA infection. (A) Experimental design of panels B-E. Briefly TILs of 6 B16.OVA tumors
(21 days-post engraftment) were pooled before marker based cell sorting (Supplementary Figure 3A) and 300 isolated cells were transferred to each recipient B6
mice (n = 5–6/group). The same day recipients were infected with 2000 cfu Lm-OVA. (B) Representative dotplots and quantification of the percentage of transferred
OT1 cells in total CD8+ T cells following the gating strategy of Supplementary Figure 3B. n.d: non-detected. Representative of two independent experiments.
(C) Representative dotplots and quantification of Tcf1+ cells in total transferred OT1 cells. (D) Representative dotplots and quantification of the percentage of IFNγ+,
TNFα+ and double IFNγ+ TNFα+ cells in total transferred OT1 cells following the gating strategy of Supplementary Figure 3C. (E) IFNγ median fluorescent intensity
(MFI) and TNFα MFI in IFNγ+ and TNFα+ transferred OT1 cells respectively. (B–E) show analysis of transferred OT1 cells from spleens of secondary hosts 7 days
after Lm-OVA infection. (D,E) Show ex vivo analysis of OT1 cells restimulated with SIINFEKL peptide. A 1-way ANOVA followed by Tukey’s multiple comparison test in
panel B and an unpaired t-test between mice receiving CD39− vs. CD39+ Tim3− Slamf6+ PD1+ OT1 cells in panels (D,E) was performed. Bars represent the mean
± SEM and each dot a mouse (n = 2–6/group).
insights into the heterogeneity of tumor antigen-specific CD8
TILs revealed the existence of a small subset of memory-like
PD-1+ CD8 TIL with high proliferation potential and self-
renewal capacity, the Tpes.
By transcriptomic and flow cytometry analyses of CD8
TILs from murine B16 and human primary melanoma,
we found that Tpes can be efficiently captured by gating
on Tim3- Slamf6+ CD39– cells. Indeed, this CD8T cell
subset yielded maximum enrichment for Tcf1+ cells among
PD-1+ TILs. Furthermore, adoptively transferred CD39–
Tim3– Slamf6+ TILs exhibited increased persistence and
functionality in recall responses to the Lm-OVA acute infection,
compared to the CD39+ counterparts. This is consistent with
previous reports associating CD39 with terminally differentiated
exhausted CD8T cells (16, 26, 27). Previous reports (28–30)
described CXCR5 as a marker of CD8T cells with stem-
cell like properties as Tpes. However, in the analyzed mouse
and human melanoma RNAseq datasets CXCR5 was not
enriched in Tpes (Supplementary Tables 1, 2), neither allowed
identification of Tcf1+ cells by flow cytometry in B16.OVA
tumors (Supplementary Figure 2B). Thus, the ability of CXCR5
staining to identify cells with stem-cell like properties may be
context dependent.
Hence, we conclude that our proposed gating strategy
represents an optimal trade-off between enriching for
tumor-specific TILs with high-affinity and preserving
recall capacity.
Altogether, we show that selection of CD39– Tim3– Slamf6+
PD-1+ TILs enables enrichment of tumor specific Tcf1+ PD-
1+ TILs Tpe that may enhance efficacy of adoptive cell transfer
therapies in cancer patients.
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